Wednesday, June 10, 2026

Patent intelligence · US

US 2025222125

Anti-FGFR2b Antibodies, Conjugates and Methods of Use

granted A61K 47/ 68 A IA61K/4768037A61K/476849A61K/476889
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 25
Patent details — US 2025222125
Jurisdiction
US
Status
granted
Grant date
Jul 10, 2025
Expiration
Jul 5, 2045
Applicant
BEIGENE LTD [KY]
CPC classes
A61K 47/ 68 A I, A61K/4768037, A61K/476849, A61K/476889
View on Google Patents ↗

Quick answer

US 2025222125 (Anti-FGFR2b Antibodies, Conjugates and Methods of Use) is held by BEIGENE LTD [KY]. Status: granted. Granted Jul 10, 2025. Expires Jul 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
BEIGENE LTD [KY]
Grant date
Expiration
Claims
CPC classes
A61K 47/ 68 A I, A61K/4768037, A61K/476849, A61K/476889, A61P 35/ 00 A I, A61P/3500

More from BEIGENE LTD [KY]

Related pharmaceutical patents in our USPTO index.

  1. WO 2025252204

    DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF

    BEIGENE SUZHOU CO LTD [CN] · Expires Dec 6, 2045

    granted
  2. AU 2025242171

    A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    BEIGENE SWITZERLAND GMBH [CH] · Expires Dec 6, 2045

    granted
  3. WO 2025232885

    PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON

    BEIGENE SUZHOU CO LTD [CN] · Expires Nov 8, 2045

    granted
  4. WO 2025218772

    FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS

    BEIGENE SUZHOU CO LTD [CN] · Expires Oct 18, 2045

    granted
  5. WO 2025214466

    CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS

    BEIGENE GUANGZHOU BIOLOGICS MFG CO LTD [CN] · Expires Oct 11, 2045

    granted
  6. WO 2025201453

    COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS

    BEIGENE SUZHOU CO LTD [CN] · Expires Sep 27, 2045

    granted
  7. US 2025304535

    KAT6 Inhibitors

    BEIGENE SWITZERLAND GMBH [CH] · Expires Sep 27, 2045

    granted
  8. US 2025290040

    GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE

    BEIGENE SWITZERLAND GMBH [CH] · Expires Sep 13, 2045

    granted

Frequently asked questions

What is US patent 2025222125?

US 2025222125 (Anti-FGFR2b Antibodies, Conjugates and Methods of Use) is held by BEIGENE LTD [KY]. Status: granted. Granted Jul 10, 2025. Expires Jul 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2025222125?

BEIGENE LTD [KY] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2025222125 expire?

Our index shows an expiration date of Jul 5, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.